Investor Overview

Investor Overview

Corporate ProfilescPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery — with the goal of transforming infused therapies, advancing patient care and reducing healthcare costs.

Stock Quote

(Common Stock)
Exchange
Volume
Today's Open
Previous Close
Data as of 11/21/24 12:22 AM EST

Minimum 15 minutes delayed. Source:

Stock Chart

Current News

November 13, 2024

scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Generated 3Q 2024 net FUROSCIX ® revenue of $10.0 million , up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million
Read More >

November 6, 2024

scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024

Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET BURLINGTON, Mass. , Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric
Read More >

October 15, 2024

scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024

Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease BURLINGTON, Mass. , Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and
Read More >
Upcoming Events
There are currently no events scheduled.
Presentations
More information is coming soon.